[ad_1]
“ChrysCapital continues to keep up a strong curiosity and energetic involvement within the stake bidding technique of GLS,” sources informed ET.
“This engagement aligns with ChrysCapital’s repute for making strategic investments that yield long-term worth for all stakeholders concerned,” a supply added.
The PE agency’s curiosity has made the bidding course of an in depth one.
Glenmark Pharma’s stake sale is a procedural requirement as per the itemizing tips, the corporate has acknowledged earlier. Glenmark Pharma’s shareholding in GLS, which is 83% at present, wants to return all the way down to 75% no later than August 2024. Nevertheless, sources have indicated that the corporate might look to promote a controlling stake in GLS.Along with being a norm of the Securities and Alternate Board of India, the transfer is seen as a strategic strategy to construct a separate roadmap away from GLS. This regulatory requirement has prompted the stake sale, prompting a number of outstanding entities to precise their curiosity.Mails despatched to Glenmark Pharma and ChrysCapital have been but to elicit responses on the time of publishing the story.Together with Nirma and ChrysCapital, Sekhmet Pharmaventures backed by PE companies PAG, CX Companions and Samara Capital additionally got here up within the checklist of potential traders within the race to amass Glenmark Pharma stake in GLS.
Glenmark Pharma is the guardian of GLS however they function independently with totally different development methods and goals.
Glenmark Pharma is concentrated on constructing international manufacturers and transferring up the worth chain by creating speciality medicines comparable to Ryaltris, revolutionary medicines and sophisticated generics, whereas Glenmark Life Sciences is concentrated on scaling up its energetic pharmaceutical ingredient (API) enterprise, creating APIs and rising its contract growth and manufacturing providers enterprise.
Shares of Glenmark dropped 0.04% to shut at Rs 797.25.
[ad_2]
Source link
